302 related articles for article (PubMed ID: 27838777)
1. A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome.
Jatoi A; Grudem ME; Dockter TJ; Block MS; Villasboas JC; Tan A; Deering E; Kasi PM; Mansfield AS; Botero JP; Okuno SH; Smith DR; Fields AP
Support Care Cancer; 2017 Mar; 25(3):833-838. PubMed ID: 27838777
[TBL] [Abstract][Full Text] [Related]
2. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1.
Reeves BN; Dakhil SR; Sloan JA; Wolf SL; Burger KN; Kamal A; Le-Lindqwister NA; Soori GS; Jaslowski AJ; Kelaghan J; Novotny PJ; Lachance DH; Loprinzi CL
Cancer; 2012 Oct; 118(20):5171-8. PubMed ID: 22415454
[TBL] [Abstract][Full Text] [Related]
3. Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Shinde SS; Seisler D; Soori G; Atherton PJ; Pachman DR; Lafky J; Ruddy KJ; Loprinzi CL
Support Care Cancer; 2016 Feb; 24(2):547-553. PubMed ID: 26155765
[TBL] [Abstract][Full Text] [Related]
4. A mixed-methods feasibility trial of protein kinase C iota inhibition with auranofin in asymptomatic ovarian cancer patients.
Jatoi A; Radecki Breitkopf C; Foster NR; Block MS; Grudem M; Wahner Hendrickson A; Carlson RE; Barrette B; Karlin N; Fields AP
Oncology; 2015; 88(4):208-13. PubMed ID: 25502607
[TBL] [Abstract][Full Text] [Related]
5. Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat L; Papadopoulos K; Lange D; Leuin S; Kaufman E; Donovan D; Frederick D; Bagiella E; Tiersten A; Nichols G; Garrett T; Savage D; Antman K; Hesdorffer CS; Balmaceda C
Clin Cancer Res; 2001 May; 7(5):1192-7. PubMed ID: 11350883
[TBL] [Abstract][Full Text] [Related]
6. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias.
Jacobson SD; Loprinzi CL; Sloan JA; Wilke JL; Novotny PJ; Okuno SH; Jatoi A; Moynihan TJ
J Support Oncol; 2003; 1(4):274-8. PubMed ID: 15334869
[TBL] [Abstract][Full Text] [Related]
7. A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2.
Tawfik B; Dayao ZR; Brown-Glaberman UA; Pankratz VS; Lafky JM; Loprinzi CL; Barton DL
Support Care Cancer; 2023 Oct; 31(12):637. PubMed ID: 37847317
[TBL] [Abstract][Full Text] [Related]
8. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1.
Loprinzi CL; Reeves BN; Dakhil SR; Sloan JA; Wolf SL; Burger KN; Kamal A; Le-Lindqwister NA; Soori GS; Jaslowski AJ; Novotny PJ; Lachance DH
J Clin Oncol; 2011 Apr; 29(11):1472-8. PubMed ID: 21383290
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
[TBL] [Abstract][Full Text] [Related]
10. Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?
Balko RA; Hendrickson AW; Grudem ME; Klampe CM; Jatoi A
Am J Hosp Palliat Care; 2019 Jan; 36(1):72-75. PubMed ID: 29983087
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
12. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).
Pachman DR; Qin R; Seisler D; Smith EM; Kaggal S; Novotny P; Ruddy KJ; Lafky JM; Ta LE; Beutler AS; Wagner-Johnston ND; Staff NP; Grothey A; Dougherty PM; Cavaletti G; Loprinzi CL
Support Care Cancer; 2016 Dec; 24(12):5059-5068. PubMed ID: 27534963
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Davis ID; Kiers L; MacGregor L; Quinn M; Arezzo J; Green M; Rosenthal M; Chia M; Michael M; Bartley P; Harrison L; Daly M
Clin Cancer Res; 2005 Mar; 11(5):1890-8. PubMed ID: 15756015
[TBL] [Abstract][Full Text] [Related]
14. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
Loven D; Levavi H; Sabach G; Zart R; Andras M; Fishman A; Karmon Y; Levi T; Dabby R; Gadoth N
Eur J Cancer Care (Engl); 2009 Jan; 18(1):78-83. PubMed ID: 19473225
[TBL] [Abstract][Full Text] [Related]
15. Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.
Sundar R; Jeyasekharan AD; Pang B; Soong RC; Kumarakulasinghe NB; Ow SG; Ho J; Lim JS; Tan DS; Wilder-Smith EP; Bandla A; Tan SS; Asuncion BR; Fazreen Z; Hoppe MM; Putti TC; Poh LM; Goh BC; Lee SC
PLoS One; 2016; 11(10):e0164319. PubMed ID: 27716814
[TBL] [Abstract][Full Text] [Related]
16. Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy.
Flatters SJ; Xiao WH; Bennett GJ
Neurosci Lett; 2006 Apr; 397(3):219-23. PubMed ID: 16406309
[TBL] [Abstract][Full Text] [Related]
17. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.
Pachman DR; Dockter T; Zekan PJ; Fruth B; Ruddy KJ; Ta LE; Lafky JM; Dentchev T; Le-Lindqwister NA; Sikov WM; Staff N; Beutler AS; Loprinzi CL
Support Care Cancer; 2017 Nov; 25(11):3407-3416. PubMed ID: 28551844
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of duloxetine for Paclitaxel-induced peripheral neuropathy treatment in gynecological cancer patients.
Otake A; Yoshino K; Ueda Y; Sawada K; Mabuchi S; Kimura T; Kobayashi E; Isobe A; Egawa-Takata T; Matsuzaki S; Fujita M; Kimura T
Anticancer Res; 2015 Jan; 35(1):359-63. PubMed ID: 25550572
[TBL] [Abstract][Full Text] [Related]
19. Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity.
Tsutsumi K; Kaname T; Shiraishi H; Kawashiri T; Egashira N
J Pharmacol Sci; 2016 Jun; 131(2):146-9. PubMed ID: 27262900
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
